^
TNFRSF8 positive
HL
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
HL
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HL
carmustine
Sensitive: A1 - Approval
No biomarker
HL
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
HL
nivolumab
Sensitive: A1 - Approval
No biomarker
HL
AK105
Sensitive: A1 - Approval
No biomarker
HL
AB122
Sensitive: A1 - Approval
No biomarker
HL
R-CHOP
Sensitive: A2 - Guideline
No biomarker
HL
rituximab
Sensitive: A2 - Guideline
No biomarker
HL
R-CVP
Sensitive: A2 - Guideline
No biomarker
HL
bortezomib
Sensitive: A2 - Guideline
No biomarker
HL
everolimus
Sensitive: A2 - Guideline
No biomarker
HL
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
No biomarker
HL
bendamustine
Sensitive: A2 - Guideline
No biomarker
HL
nivolumab + brentuximab vedotin
Sensitive: A2 - Guideline
No biomarker
HL
lenalidomide
Sensitive: A2 - Guideline
No biomarker
HL
GemOx
Sensitive: A2 - Guideline
No biomarker
HL
ICE
Sensitive: A2 - Guideline
No biomarker
HL
ESHAP
Sensitive: A2 - Guideline
No biomarker
HL
DHAP
Sensitive: A2 - Guideline
No biomarker
HL
R-ESHAP
Sensitive: A2 - Guideline
No biomarker
HL
MINE
Sensitive: A2 - Guideline
CHD8 mutation
HL
sintilimab
Resistant: C3 – Early Trials
CELF2 mutation
HL
sintilimab
Resistant: C3 – Early Trials
ABCC2 underexpression
HL
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
PD-1 underexpression
HL
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
CD163 overexpression
HL
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
CD14 overexpression
HL
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
TNFRSF8 positive
HL
CD30.CAR-T cell therapy
Sensitive: C3 – Early Trials
TNFRSF14 mutation
HL
sintilimab
Resistant: C3 – Early Trials
MHC-II expression
HL
nivolumab
Sensitive: C3 – Early Trials
CASP3 underexpression + BCL2 positive
HL
ABVD
Resistant: C3 – Early Trials
CASP3 overexpression
HL
ABVD
Sensitive: C3 – Early Trials
BCL2 expression
HL
ABVD
Resistant: C3 – Early Trials
CASP3 overexpression + BCL2 negative
HL
ABVD
Sensitive: C3 – Early Trials
B2M mutation
HL
sintilimab
Resistant: C3 – Early Trials
TNFRSF8 overexpression
HL
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
Chr amplification(9)(p24.1)
HL
nivolumab
Sensitive: C3 – Early Trials
BCL2 overexpression
HL
venetoclax
Resistant: D – Preclinical
CD123 positive
HL
VIP943
Sensitive: D – Preclinical
BCL2 expression
HL
venetoclax
Sensitive: D – Preclinical
XPO1 E571K
HL
venetoclax + selinexor
Sensitive: D – Preclinical
XPO1 E571K
HL
venetoclax
Sensitive: D – Preclinical